Trials / Completed
CompletedNCT04831684
Novel mGluR5 Modulator Effects on Alcohol Drinking and MRI Outcomes
Effects of a Novel mGluR5 Negative Allosteric Modulator on Alcohol Drinking, Neurochemistry, and Brain Reactivity to Alcohol Cues in Alcohol Use Disorder
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 79 (actual)
- Sponsor
- Medical University of South Carolina · Academic / Other
- Sex
- All
- Age
- 21 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the effects of the medication GET73 among non-treatment-seeking individuals who regularly drink alcohol. Participants in the study will take GET73 or placebo for an 8-day study. There are 4 study visits including 2 MRI scans.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Participants will be getting placebo for 8 days of dosing. |
| DRUG | GET73 | Participants will be getting GET73 for 8 days of dosing. |
Timeline
- Start date
- 2021-09-15
- Primary completion
- 2025-12-29
- Completion
- 2025-12-29
- First posted
- 2021-04-05
- Last updated
- 2026-02-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04831684. Inclusion in this directory is not an endorsement.